纳米材料在动脉粥样硬化性心血管疾病中的应用进展

doi:10.11958/20251227

天津医药 ›› 2025, Vol. 53 ›› Issue (5): 556-560.doi: 10.11958/20251227

• 综述 • 上一篇

纳米材料在动脉粥样硬化性心血管疾病中的应用进展

邓子昊¹(), 黄欣扬¹, 钟坤江¹, 赵博²^,^△()

1 首都医科大学附属北京世纪坛医院（邮编100038）
2 首都医科大学附属北京世纪坛医院心血管内科

收稿日期:2025-03-25 修回日期:2025-04-23 出版日期:2025-05-15 发布日期:2025-05-28
通讯作者: △ E-mail：zhaobo3009@bjsjth.cn E-mail:13811055741@163.com;zhaobo3009@bjsjth.cn
作者简介:邓子昊（2003），男，本科在读，主要从事心血管内科方面研究。E-mail：13811055741@163.com

The application progress of nanomaterials in atherosclerotic cardiovascular disease

DENG Zihao¹(), HUANG Xinyang¹, ZHONG Kunjiang¹, ZHAO Bo²^,^△()

1 Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China
2 Department of Cardiology, Beijing Shijitan Hospital, Capital Medical University

Received:2025-03-25 Revised:2025-04-23 Published:2025-05-15 Online:2025-05-28
Contact: △ E-mail：zhaobo3009@bjsjth.cn E-mail:13811055741@163.com;zhaobo3009@bjsjth.cn

邓子昊, 黄欣扬, 钟坤江, 赵博. 纳米材料在动脉粥样硬化性心血管疾病中的应用进展[J]. 天津医药, 2025, 53(5): 556-560.

DENG Zihao, HUANG Xinyang, ZHONG Kunjiang, ZHAO Bo. The application progress of nanomaterials in atherosclerotic cardiovascular disease[J]. Tianjin Medical Journal, 2025, 53(5): 556-560.

摘要/Abstract

摘要：

动脉粥样硬化性心血管疾病（ASCVD）是一种以动脉内膜病变为特征的慢性进行性疾病，其传统疗法具有局限性。近年来，纳米载药系统在靶向递送、提高药物安全性与有效性等方面展现出显著优势，为ASCVD的精准诊疗提供了新的策略。纳米材料主要包括聚合物纳米颗粒、脂质纳米颗粒、无机纳米颗粒、生物仿生纳米颗粒等，可有效干预ASCVD的关键病理环节，通过调控巨噬细胞平衡、保护内皮细胞功能、维持平滑肌细胞收缩表型及调节血小板活性，发挥治疗作用。该文综述了不同类型纳米材料在ASCVD防治中的应用特点与研究进展，并对该领域的挑战与前景进行了展望。

关键词: 动脉粥样硬化, 纳米技术, 药物载体, 药物释放系统, 心血管疾病

Abstract:

Atherosclerotic cardiovascular diseases (ASCVD) are chronic progressive diseases characterized by endothelial dysfunction, and their traditional therapies have limitations. In recent years, nanocarrier systems have demonstrated significant advantages in targeted delivery, enhancing drug safety and efficacy, thereby offering new strategies for precise diagnosis and treatment of ASCVD. Nanomaterials, including polymer nanoparticles, lipid nanoparticles, inorganic nanoparticles and bio-inspired nanoparticles, can effectively intervene key pathological processes of ASCVD. They achieve therapeutic effects by regulating macrophage balance, preserving endothelial cell function, maintaining smooth muscle cell contractile phenotype and modulating platelet activity. This review summarizes the application characteristics and research progress of different types of nanomaterials in the prevention and treatment of ASCVD, and provides insights into the challenges and future prospects of this field.

Key words: atherosclerosis, nanotechnology, drug carriers, drug delivery systems, cardiovascular diseases

中图分类号:

R543.3

参考文献 44

[1]	SURMA S, FILIPIAK K J. Inflammation and autoimmunity in atherosclerosis[J]. Reumatologia, 2022, 60(1):1-3. doi:10.5114/reum.2022.113364.
[2]	MURRAY C, GBD 2021 COLLABORATORS. Findings from the Global Burden of Disease Study 2021[J]. Lancet, 2024, 403(10440):2259-2262. doi:10.1016/S0140-6736(24)00769-4.
[3]	SORIA-FLORIDO M T, CASTAÑER O, LASSALE C, et al. Dysfunctional high-density lipoproteins are associated with a greater incidence of acute coronary syndrome in a population at high cardiovascular risk:a nested case-control study[J]. Circulation, 2020, 141(6):444-453. doi:10.1161/CIRCULATIONAHA.119.041658.
[4]	FRĄK W, WOJTASIŃSKA A, LISIŃSKA W, et al. Pathophysiology of cardiovascular diseases:new insights into molecular mechanisms of atherosclerosis, arterial hypertension, and coronary artery disease[J]. Biomedicines, 2022, 10(8):1938. doi:10.3390/biomedicines10081938.
[5]	ZHU N, GUO Z F, KAZAMA K, et al. Epigenetic regulation of vascular smooth muscle cell phenotypic switch and neointimal formation by PRMT5[J]. Cardiovasc Res, 2023, 119(12):2244-2255. doi:10.1093/cvr/cvad110.
[6]	RIDKER P M, MOORTHY M V, COOK N R, et al. Inflammation,cholesterol,lipoprotein(a),and 30-year cardiovascular outcomes in women[J]. N Engl J Med, 2024, 391(22):2087-2097. doi:10.1056/NEJMoa2405182.
[7]	NAKAMURA M, SADOSHIMA J. Mechanisms of physiological and pathological cardiac hypertrophy[J]. Nat Rev Cardiol, 2018, 15(7):387-407. doi:10.1038/s41569-018-0007-y.
[8]	WEBER B N, GILES J T, LIAO K P. Shared inflammatory pathways of rheumatoid arthritis and atherosclerotic cardiovascular disease[J]. Nat Rev Rheumatol, 2023, 19(7):417-428. doi:10.1038/s41584-023-00969-7.
[9]	HUANG X, SONG J, ZHANG X, et al. Understanding drug interactions in antiplatelet therapy for atherosclerotic vascular disease:a systematic review[J]. CNS Neurosci Ther, 2025, 31(2):e70258. doi:10.1111/cns.70258.
[10]	GAWAZ M, GEISLER T, BORST O. Current concepts and novel targets for antiplatelet therapy[J]. Nat Rev Cardiol, 2023, 20(9):583-599. doi:10.1038/s41569-023-00854-6.
[11]	SURMA S, SAHEBKAR A, BANACH M. Coffee or tea:Anti-inflammatory properties in the context of atherosclerotic cardiovascular disease prevention[J]. Pharmacol Res, 2023, 187:106596. doi:10.1016/j.phrs.2022.106596.
[12]	BARUNGI S, HERNÁNDEZ-CAMARERO P, MORENO-TERRIBAS G, et al. Clinical implications of inflammation in atheroma formation and novel therapies in cardiovascular diseases[J]. Front Cell Dev Biol, 2023, 11:1148768. doi:10.3389/fcell.2023.1148768.
[13]	ISSELBACHER E M, PREVENTZA O, HAMILTON BLACK J 3rd, et al. 2022 ACC/AHA Guideline for the diagnosis and management of aortic disease: a report of the american heart association/American college of cardiology joint committee on clinical practice guidelines[J]. Circulation, 2022, 146(24):e334-e482. doi:10.1161/CIR.0000000000001106.
[14]	NI Z, YU H, WANG L, et al. Recent research progress on polyphosphazene-based drug delivery systems[J]. J Mater Chem B, 2020, 8(8):1555-1575. doi:10.1039/c9tb02517k.
[15]	MAHJOUBIN-TEHRAN M, KOVANEN P T, XU S, et al. Cyclodextrins:potential therapeutics against atherosclerosis[J]. Pharmacol Ther, 2020, 214:107620. doi:10.1016/j.pharmthera.2020.107620.
[16]	LI S, SUN S, LUO J, et al. Polymer single-chain nanoparticles:shaping solid surfactants[J]. Macromol Rapid Commun, 2024, 45(21):e2400393. doi:10.1002/marc.202400393.
[17]	SARFRAZ M, AFZAL A, YANG T, et al. Development of dual drug loaded nanosized liposomal formulation by a reengineered ethanolic injection method and its pre-clinical pharmacokinetic studies[J]. Pharmaceutics, 2018, 10(3):151. doi:10.3390/pharmaceutics10030151.
[18]	CHANG C Y, HUANG S H, CHEN C Y, et al. Monocyte-adhesive peptidyl liposomes for harnessing monocyte homing to tumor tissues[J]. J Control Release, 2025, 382:113672. doi:10.1016/j.jconrel.2025.113672.
[19]	YU S, XIA G, YANG N, et al. Noble metal nanoparticle-based photothermal therapy:development and application in effective cancer therapy[J]. Int J Mol Sci, 2024, 25(11):5632. doi:10.3390/ijms25115632.
[20]	DOCKERY L T, DANIEL M C. Targeted doxorubicin-loaded dendronized gold nanoparticles[J]. Pharmaceutics, 2023, 15(8):2103. doi:10.3390/pharmaceutics15082103.
[21]	IMRAISH A, THIAB T A, ZIHLIF M, et al. Anti-inflammatory and antioxidant potential of green synthesized iron zinc oxide(Fe0.25-ZnO)nanoparticles of the elaeagnus angustifolia[J]. Chem Biodivers, 2024, 21(9):e202401060. doi:10.1002/cbdv.202401060.
[22]	YANG L, ZANG G, LI J, et al. Cell-derived biomimetic nanoparticles as a novel drug delivery system for atherosclerosis: predecessors and perspectives[J]. Regen Biomater, 2020, 7(4):349-358. doi:10.1093/rb/rbaa019.
[23]	CHEN J, ZHANG X, MILLICAN R, et al. Recent advances in nanomaterials for therapy and diagnosis for atherosclerosis[J]. Adv Drug Deliv Rev, 2021, 170:142-199. doi:10.1016/j.addr.2021.01.005.
[24]	PANG L, ZHANG C, QIN J, et al. A novel strategy to achieve effective drug delivery:exploit cells as carrier combined with nanoparticles[J]. Drug Deliv, 2017, 24(1):83-91. doi:10.1080/10717544.2016.1230903.
[25]	WANG Y, ZHANG K, LI T, et al. Macrophage membrane functionalized biomimetic nanoparticles for targeted anti-atherosclerosis applications[J]. Theranostics, 2021, 11(1):164-180. doi:10.7150/thno.47841.
[26]	WANG J, WANG J, ZHONG J, et al. LRG1 promotes atherosclerosis by inducing macrophage M1-like polarization[J]. Proc Natl Acad Sci U S A, 2024, 121(35):e2405845121. doi:10.1073/pnas.2405845121.
[27]	THEOFILIS P, OIKONOMOU E, TSIOUFIS K, et al. The role of macrophages in atherosclerosis:pathophysiologic mechanisms and treatment considerations[J]. Int J Mol Sci, 2023, 24(11):9568. doi:10.3390/ijms24119568.
[28]	KOJIMA Y, VOLKMER J P, MCKENNA K, et al. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis[J]. Nature, 2016, 536(7614):86-90. doi:10.1038/nature18935.
[29]	GHOLAMIN S, MITRA S S, FEROZE A H, et al. Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors[J]. Sci Transl Med, 2017, 9(381):eaaf2968. doi:10.1126/scitranslmed.aaf2968.
[30]	CUI Y, YU H, BU Z, et al. Focus on the role of the NLRP3 inflammasome in multiple sclerosis:pathogenesis,diagnosis,and therapeutics[J]. Front Mol Neurosci, 2022, 15:894298. doi:10.3389/fnmol.2022.894298.
[31]	LUO Q, DAI L, LI J, et al. Intracellular and extracellular synergistic therapy for restoring macrophage functions via anti-CD47 antibody-conjugated bifunctional nanoparticles in atherosclerosis[J]. Bioact Mater, 2024, 34:326-337. doi:10.1016/j.bioactmat.2023.12.024.
[32]	WU Z, ZHOU M, TANG X, et al. Carrier-free trehalose-based nanomotors targeting macrophages in inflammatory plaque for treatment of atherosclerosis[J]. ACS Nano, 2022, 16(3):3808-3820. doi:10.1021/acsnano.1c08391.
[33]	ZHU L, ZHONG Y, YAN M, et al. Macrophage membrane-encapsulated dopamine-modified poly cyclodextrin multifunctional biomimetic nanoparticles for atherosclerosis therapy[J]. ACS Appl Mater Interfaces, 2024, 16(25):32027-32044. doi:10.1021/acsami.4c04431.
[34]	LIU D, YANG A, LI Y, et al. Targeted delivery of rosuvastatin enhances treatment of hyperhomocysteinemia-induced atherosclerosis using macrophage membrane-coated nanoparticles[J]. J Pharm Anal, 2024, 14(9):100937. doi:10.1016/j.jpha.2024.01.005.
[35]	LIBBY P, HANSSON G K. From focal lipid storage to systemic inflammation:JACC review topic of the week[J]. J Am Coll Cardiol, 2019, 74(12):1594-1607. doi:10.1016/j.jacc.2019.07.061.
[36]	WANG S, WANG Y, LAI X, et al. Minimalist nanocomplex with dual regulation of endothelial function and inflammation for targeted therapy of inflammatory vascular diseases[J]. ACS Nano, 2023, 17(3):2761-2781. doi:10.1021/acsnano.2c11058.
[37]	LIU J, YU X, BRAUCHT A, et al. N-cadherin targeted melanin nanoparticles reverse the endothelial-mesenchymal transition in vascular endothelial cells to potentially slow the progression of atherosclerosis and cancer[J]. ACS Nano, 2024, 18(11):8229-8247. doi:10.1021/acsnano.3c12281.
[38]	DURHAM A L, SPEER M Y, SCATENA M, et al. Role of smooth muscle cells in vascular calcification: implications in atherosclerosis and arterial stiffness[J]. Cardiovasc Res, 2018, 114(4):590-600. doi:10.1093/cvr/cvy010.
[39]	CHIN D D, POON C, WANG J, et al. miR-145 micelles mitigate atherosclerosis by modulating vascular smooth muscle cell phenotype[J]. Biomaterials, 2021, 273:120810. doi:10.1016/j.biomaterials.2021.120810.
[40]	YU J, MA Y, ZHANG X, et al. β-cyclodextrin and hyaluronic acid-modified targeted nanodelivery system for atherosclerosis prevention[J]. ACS Appl Mater Interfaces, 2024, 16(27):35421-35437. doi:10.1021/acsami.4c01540.
[41]	HUILCAMAN R, VENTURINI W, FUENZALIDA L, et al. Platelets,a key cell in inflammation and atherosclerosis progression[J]. Cells, 2022, 11(6):1014. doi:10.3390/cells11061014.
[42]	COENEN D M, HEINZMANN A, KAREL M, et al. The multifaceted contribution of platelets in the emergence and aftermath of acute cardiovascular events[J]. Atherosclerosis, 2021, 319:132-141. doi:10.1016/j.atherosclerosis.2020.12.017.
[43]	FONTANA F, MOLINARO G, MORONI S, et al. Biomimetic platelet-cloaked nanoparticles for the delivery of anti-inflammatory curcumin in the treatment of atherosclerosis[J]. Adv Healthc Mater, 2024, 13(15):e2302074. doi:10.1002/adhm.202302074.
[44]	CHAI Y, SHANGGUAN L, YU H, et al. Near infrared light-activatable platelet-mimicking NIR-Ⅱ NO nano-prodrug for precise atherosclerosis theranostics[J]. Adv Sci(Weinh), 2024, 11(3):e2304994. doi:10.1002/advs.202304994.

纳米材料在动脉粥样硬化性心血管疾病中的应用进展

The application progress of nanomaterials in atherosclerotic cardiovascular disease

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

参考文献 44

相关文章 15

编辑推荐

Metrics

本文评价

[1]	胡紫月, 郑茹瑜, 刘丹, 唐姗, 阚艳敏, 经翔, 李倩. 颈动脉粥样硬化斑块近心端角度与新生血管评分对脑梗死的预测价值[J]. 天津医药, 2025, 53(4): 439-443.
[2]	马良, 胡立影, 石羽, 龙刚. 光学相干断层扫描血管成像技术在慢性肾脏病临床评估中的应用进展[J]. 天津医药, 2024, 52(8): 882-887.
[3]	天津市医学会神经外科学分会. 颅外段颈部动脉粥样硬化性疾病外科治疗京津冀专家共识[J]. 天津医药, 2024, 52(3): 225-230.
[4]	谷巍, 张惠娜, 侯丽萍, 于敏, 程黎蓉. 脂质相关指数与糖尿病肾病相关性研究[J]. 天津医药, 2024, 52(12): 1308-1312.
[5]	张贵婷, 何超. oxLDL/β2GPⅠ/aβ2GPⅠ复合物通过TLR4/MyD88/NF-κB途径促进血管内皮细胞血管生成[J]. 天津医药, 2024, 52(11): 1131-1136.
[6]	刘艳文, 刘水清, 林少伟, 刘协红. 毛蕊花糖苷调节HMGB1/RAGE/NF-κB信号通路对动脉粥样硬化大鼠内皮功能障碍的影响[J]. 天津医药, 2023, 51(12): 1339-1343.
[7]	朱云林, 殷广莉, 戴平涛. 颈动脉超声及血清HbA1c、FIB对急性前循环脑梗死的评估价值分析[J]. 天津医药, 2022, 50(9): 948-952.
[8]	王华, 何雄. 护心通络方通过干预CETP介导脂质代谢抗兔动脉粥样硬化的实验研究[J]. 天津医药, 2022, 50(8): 827-831.
[9]	林玉凤, 汪志云, 王雪松△. 丁苯酞下调血清脂蛋白相关磷脂酶A2改善急性大动脉#br# 粥样硬化型脑梗死患者预后的临床观察#br#[J]. 天津医药, 2022, 50(5): 544-547.
[10]	胡明哲, 陈香岩, 吴光亮, 乔利军, 蔡业锋△. 中性粒细胞淋巴细胞比值、淋巴细胞单核细胞比值与症状性颅内动脉粥样硬化性狭窄的关系#br#[J]. 天津医药, 2022, 50(5): 493-497.
[11]	黄秋阳, 王伟, 罗书, 郑文武, 冯健, 叶强, 郑舒展. PM_2.5通过TLR4破坏自噬流加重Raw264.7巨噬细胞炎症反应[J]. 天津医药, 2022, 50(11): 1139-1145.
[12]	郭丹丹, 曹丽, 张凯, 周贵明. 中老年女性颈动脉斑块发生及稳定性相关危险因素分析[J]. 天津医药, 2021, 49(7): 719-722.
[13]	许景涵, 左俊荣, 韩楚仪, 李婷婷, 金冬霞, 赵福梅, 丛洪良. PCSK9抑制剂在ox-LDL诱导HUVECs损伤中的保护作用研究[J]. 天津医药, 2021, 49(7): 683-688.
[14]	韩鹏, 马静, 张楠 , 肖健勇 , 王静娴 , 王缘 , 许仕博, 高静 , 刘寅 . 天津市35岁以上居民对急性心肌梗死危险因素的知晓现状及影响因素 #br#[J]. 天津医药, 2021, 49(6): 651-655.
[15]	翁嘉懿, 殷云杰, 马雪兴, 李渊, 陈璐, 何洪涛, 徐桂冬, 孙康云. CD137-CD137L信号通路通过活化TNF受体相关因子6促进小鼠动脉粥样硬化斑块内血管新生#br#[J]. 天津医药, 2021, 49(4): 384-389.